published meta-analysis   sensitivity analysis   studies

neutralizing antibody in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death or transfer to ICUdetailed resultsLopardo, 2021 0.65 [0.35; 1.22] 0.65[0.35; 1.22]Lopardo, 202110%241NAnot evaluable deathsdetailed resultsLopardo, 2021 0.57 [0.24; 1.37] 0.57[0.24; 1.37]Lopardo, 202110%241NAnot evaluable clinical improvementdetailed resultsLopardo, 2021 1.61 [0.75; 3.49] 1.61[0.75; 3.49]Lopardo, 202110%241NAnot evaluable ICU admissiondetailed resultsLopardo, 2021 0.67 [0.35; 1.28] 0.67[0.35; 1.28]Lopardo, 202110%241NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:15 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 729,887,742,878,975,570,771,888,1141,690,880,1255 - roots T: 290